| HOME >> BIOLOGY >> TECHNOLOGY |
Bionovo, Inc.
(A Development Stage Company)
Condensed Statements of Operations
(Unaudited)
Accumulated from
February 1,
2002
(Date of inception)
Three months to
ended March 31, March 31,
2008 2007 2008
Revenues $- $3,750 $659,490
Operating expenses:
Research and development 2,387,393 2,788,668 18,179,598
General and administrative 1,822,027 694,921 9,273,794
Merger cost - - 1,964,065
Total operating expenses 4,209,420 3,483,589 29,417,457
Loss from operations (4,209,420) (3,479,839) (28,757,967)
Change in fair value of
warrant liability - - 831,288
Interest income 306,192 149,712 1,374,609
Interest expense (26,537) (14,081) (263,554)
Other income (expense) (15,575) - 129,321
Loss before income tax (3,945,340) (3,344,208) (26,686,303)
Income tax provision (3,256) (800) (12,258)
Net loss $(3,948,596) (3,345,008) $(26,698,561)
Basic and diluted net loss per $(0.05) $(0.05) $(0.70)
Shares used in computing
basic and diluted net loss
per com
'/>"/>
| SOURCE Bionovo, Inc. Copyright©2008 PR Newswire. All rights reserved |